Christopher Ryan Sullivan Sells 10,185 Shares of Avalo Therapeutics (NASDAQ:AVTX) Stock

Avalo Therapeutics, Inc. (NASDAQ:AVTX) CFO Christopher Sullivan sold 10,185 shares of the business’s stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $17.62, for a total transaction of $179,459.70. Following the transaction, the chief financial officer owned 39,900 shares in the company, valued at approximately $703,038. The trade was a 20.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Avalo Therapeutics Price Performance

Shares of AVTX stock opened at $16.12 on Friday. The stock has a market cap of $864.52 million, a P/E ratio of -3.69 and a beta of 0.78. The company has a fifty day moving average price of $19.07 and a two-hundred day moving average price of $17.05. Avalo Therapeutics, Inc. has a one year low of $9.54 and a one year high of $24.27.

Avalo Therapeutics (NASDAQ:AVTX) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.25). As a group, equities research analysts anticipate that Avalo Therapeutics, Inc. will post -2.69 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. Bank of America started coverage on Avalo Therapeutics in a research report on Friday, June 12th. They set a “buy” rating and a $35.00 price target on the stock. HC Wainwright cut their price objective on Avalo Therapeutics from $35.00 to $30.00 and set a “buy” rating for the company in a research report on Friday, August 7th. Weiss Ratings raised Avalo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. BTIG Research restated a “buy” rating and issued a $58.00 price target on shares of Avalo Therapeutics in a research note on Tuesday, June 16th. Finally, Leerink Partners started coverage on Avalo Therapeutics in a research note on Monday, July 6th. They issued an “outperform” rating and a $38.00 price target on the stock. Twelve analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Avalo Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $45.10.

Institutional Investors Weigh In On Avalo Therapeutics

Institutional investors have recently modified their holdings of the business. Squarepoint Ops LLC grew its position in Avalo Therapeutics by 624.9% during the second quarter. Squarepoint Ops LLC now owns 589,245 shares of the company’s stock worth $10,889,000 after buying an additional 507,960 shares in the last quarter. California State Teachers Retirement System acquired a new position in Avalo Therapeutics in the 2nd quarter valued at $196,000. Seven Fleet Capital Management LP raised its holdings in Avalo Therapeutics by 34.3% in the 2nd quarter. Seven Fleet Capital Management LP now owns 770,765 shares of the company’s stock valued at $14,244,000 after acquiring an additional 196,882 shares in the last quarter. Braidwell LP bought a new stake in shares of Avalo Therapeutics during the 2nd quarter valued at $30,107,000. Finally, Wellington Management Group LLP bought a new stake in shares of Avalo Therapeutics during the 2nd quarter valued at $1,945,000. Institutional investors own 87.06% of the company’s stock.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.